Publications & Citations Referencing Veritas Data Research

Veritas Data Research Overview

Veritas Data Research datasets have been used across a range of peer-reviewed publications, and conference presentations to support real-world evidence (RWE) and mortality validation research. Selected examples are listed below.

Publications

Veritas Data Research

Building High-Quality, Research-Grade Multi-Source Mortality Databases in a Timely Manner

Location: ISPOR 2026 Conference Poster | Philadelphia, PA | May 2026

- Conference presentation: ISPOR 2026 Poster (PDF)
- Value in Health, Volume 29, Issue S6 | Poster MSR137 | Authors: Kyle W. McLean, PhD; Kirsty Macaulay, PhD

Description: *Demonstrates that a composite mortality database built from nine source categories significantly outperforms any single source. Composite datasets increased completeness by 41.3%, reduced median capture lag from 7 to 4 days, and corrected 25% of single-source inaccuracies.*

> **Citation:** McLean KW, Macaulay K. Building high-quality, research-grade multi-source mortality databases in a timely manner. Value Health. 2026;29(S6). Presented at: ISPOR 2026; May 2026; Philadelphia, PA. Abstract MSR137.

Enhancing Cause-of-Death Attribution Through Real-World Data Integration: A Framework to Improve Cancer Mortality Identification

Location: ASCO Annual Meeting 2026 | Journal of Clinical Oncology, Volume 44, Issue 16 Supplement

- Conference presentation: Abstract e23418 (Journal of Clinical Oncology)
- Authors: Kyle McLean; Kirsty Macaulay; Shahir Kassam-Adams

Description: *Presents the Veritas COD solution, an RWD model incorporating up to three years of longitudinal claims, diagnoses, and UMLS concept mapping to improve cause-of-death attribution. Integration of Veritas COD profiles with Connecticut state mortality data produced a 33% increase in decedents showing cancer as an underlying COD compared with state reporting alone.*

> **Citation:** McLean K, Macaulay K, Kassam-Adams S. Enhancing cause-of-death attribution through real-world data integration: A framework to improve cancer mortality identification. J Clin Oncol. 2026;44(16 suppl):e23418. doi:10.1200/JCO.2026.44.16_suppl.e23418. Presented at: ASCO Annual Meeting 2026.

Norstella / Veritas Data Research

Enhancing Clinical Trial Recruitment Through Integrated Provider Affiliation and Real-World Data-Driven HCP Targeting

Location: ISPOR 2026 Conference Poster | Philadelphia, PA | May 2026

- Conference presentation: ISPOR 2026 Poster (PDF)
- Value in Health, Volume 29, Issue S6 | Poster SA32 | Authors: Amanda Gunn, PhD (Norstella); Kyle W. McLean, PhD; Kirsty Macaulay, PhD (Veritas)

Description: *Evaluates provider-facility-system affiliation relationships to expand HCP recruitment pools beyond patient-level targeting. Successive affiliation tiers identified operationally connected HCPs not visible through employment-only targeting.*

> **Citation:** Gunn A, McLean KW, Macaulay K. Enhancing clinical trial recruitment through integrated provider affiliation and real-world data-driven HCP targeting. Value Health. 2026;29(S6). Presented at: ISPOR 2026; May 2026; Philadelphia, PA. Abstract SA32.

University of Michigan

Toward an Era of Oculomics: Association between Baseline Diabetic Retinopathy Severity and Mortality Risk in a SOURCE Consortium Cohort

Location: Ophthalmology, Volume 133, Issue 7, p852-864 | July 2026

- Peer-reviewed article: Ophthalmology (open access)
- Authors: Stephanie S. Lee, BS; Shikha Marwah, MS; Sandeepkumar Gaddam, MS; et al.; Joshua D. Stein, MD, MS, on behalf of the Collaborative (SOURCE) Consortium

Description: *Retrospective cohort study of 524,687 patients with diabetes mellitus across 15 SOURCE Ophthalmology Big Data consortium health systems, linking EHR data to National Death Index mortality data licensed from Veritas Data Research via Datavant. Found a stepwise increase in all-cause mortality risk with worsening diabetic retinopathy severity (hazard ratio up to 2.28 for proliferative DR), independent of demographic, socioeconomic, and clinical confounders.*

> **Citation**: Lee SS, Marwah S, Gaddam S, et al; Collaborative (SOURCE) Consortium. Toward an era of oculomics: association between baseline diabetic retinopathy severity and mortality risk in a SOURCE Consortium cohort. Ophthalmology. 2026;133(7):852-864.

Sarepta Therapeutics

A Real-World Target Trial Emulation of Eteplirsen, Casimersen, and Golodirsen to Evaluate Survival Among Patients with Duchenne Muscular Dystrophy

Location: Advances in Therapy | Published June 2026

- Peer-reviewed article: Advances in Therapy (open access)
- Authors: Sai Dharmarajan; Shannon Grabich; Richard Baxter; Aalok Nadkar; Carol Schermer

Description: *Real-world target trial emulation using Inovalon closed claims data linked to Datavant mortality data, sourced from the Veritas Data Research Fact of Death Mortality Index, to evaluate exon-skipping PMO therapies' effect on survival in Duchenne muscular dystrophy. Found PMO combined with glucocorticoids was associated with a substantially lower mortality risk than glucocorticoids alone (hazard ratio 0.303; 95% CI 0.119-0.769).*

> **Citation**: Dharmarajan S, Grabich S, Baxter R, Nadkar A, Schermer C. A real-world target trial emulation of eteplirsen, casimersen, and golodirsen to evaluate survival among patients with Duchenne muscular dystrophy. Adv Ther. 2026. doi:10.1007/s12325-026-03609-0

Natera

Real-World Outcomes and Circulating Tumor DNA (ctDNA) Dynamics in Patients with Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer Treated with Immune Checkpoint Inhibitors (ICI)

Location: ASCO Annual Meeting 2026 | Journal of Clinical Oncology, Volume 44, Issue 16 Supplement | May 2026

- Conference presentation: Abstract 3516 (Journal of Clinical Oncology)
- Authors: Hannah Ruth Robinson; Nicholas James Hornstein; Patrick M. Boland; et al.; Christopher Lieu

Description: *Real-world analysis of 559 patients with MSI-H metastatic colorectal cancer treated with first-line ICI, using Natera's Real-World Database with linked Signatera ctDNA results, Forian claims data, and overall survival estimated using the Veritas Data Research Fact of Death Mortality Data Index. Longitudinal ctDNA clearance was strongly associated with treatment durability, time to next treatment, and overall survival.*

> **Citation**: Robinson HR, Hornstein NJ, Boland PM, et al. Real-world outcomes and circulating tumor DNA (ctDNA) dynamics in patients with microsatellite instability-high (MSI-H) metastatic colorectal cancer (CRC) treated with immune checkpoint inhibitors (ICI). J Clin Oncol. 2026;44(16 suppl):3516. doi:10.1200/JCO.2026.44.16_suppl.3516. Presented at: ASCO Annual Meeting 2026.

[Consensus Molecular Subtypes, Mutational Features, and Circulating Tumor DNA Dynamics in Colorectal Cancer: A Real-World Clinico-Genomic Analysis]

Location: ASCO Annual Meeting 2026 | Journal of Clinical Oncology, Volume 44, Issue 16 Supplement | May 2026

- Conference presentation: Abstract 3652 (Journal of Clinical Oncology)
- Authors: Imad Shureiqi; Avinash Ramu; Vasily N. Aushev; et al.; Anthony F. Shields

Description: *Analysis of 8,456 real-world colorectal cancer cases with whole-transcriptome sequencing (Altera, Natera, Inc.) correlated with Signatera ctDNA results, with overall survival estimated using the Veritas Data Research Fact of Death Mortality Data Index. Found distinct ctDNA detection and survival patterns across consensus molecular subtypes.*

> **Citation**: Shureiqi I, Ramu A, Aushev VN, et al. Consensus molecular subtypes, mutational features, and circulating tumor DNA dynamics in colorectal cancer: a real-world clinico-genomic analysis. J Clin Oncol. 2026;44(16 suppl):3652. doi:10.1200/JCO.2026.44.16_suppl.3652. Presented at: ASCO Annual Meeting 2026.

[Real-World Assessment of ctDNA Status Post-Neoadjuvant and Adjuvant Therapy in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Curative-Intent Resection]

Location: AHPBA 2026 Annual Meeting | HPB, Volume 28, Supplement 1, S19 | March 2026

- Conference presentation: Abstract (HPB)
- Authors: S. Logarajah; A. Jomy; V. Aushev; et al.; A. Jurdi; M.C. Liu; D.R. Jeyarajah

Description: *Real-world analysis of 433 patients with pancreatic ductal adenocarcinoma undergoing curative-intent pancreatectomy, using Natera's proprietary database with linked Signatera ctDNA testing, Forian claims data, and the Veritas Data Research Fact of Death Mortality Data Index. ctDNA positivity in the molecular residual disease window was strongly prognostic of overall survival (hazard ratio 7.9) regardless of cancer stage or treatment received.*

> **Citation**: Logarajah S, Jomy A, Aushev V, et al. Real-world assessment of ctDNA status post-neoadjuvant and adjuvant therapy in patients with pancreatic ductal adenocarcinoma undergoing curative-intent resection. HPB. 2026;28(S1):S19. Presented at: AHPBA 2026 Annual Meeting; March 2026; Miami Beach, FL.

[Real-World Assessment of ctDNA Status and Survival Outcomes in Oligometastatic Colorectal Cancer Patients Undergoing Liver Metastasis-Directed Therapy]

Location: AHPBA 2026 Annual Meeting | HPB, Volume 28, Supplement 1, S160 | March 2026

- Conference presentation: Abstract (HPB)
- Authors: S. Logarajah; A. Jomy; V. Aushev; et al.; A. Jurdi; M.C. Liu; D.R. Jeyarajah

Description: *Real-world analysis of 805 colorectal cancer patients undergoing colectomy followed by liver metastasis-directed therapy, using Natera's proprietary database linked to Forian claims data and the Veritas Data Research Fact of Death Mortality Data Index. Post-treatment ctDNA-negative status was associated with significantly improved overall survival (hazard ratio 2.6).*

> **Citation**: Logarajah S, Jomy A, Aushev V, et al. Real-world assessment of ctDNA status and survival outcomes in oligometastatic colorectal cancer patients undergoing liver metastasis-directed therapy. HPB. 2026;28(S1):S160. Presented at: AHPBA 2026 Annual Meeting; March 2026; Miami Beach, FL.

Socially Determined

Social Determinants of Health Enable Early Identification of Premature Mortality Risk

Location: ISPOR 2026 Conference Poster | Philadelphia, PA | May 2026

- Conference presentation: ISPOR 2026 Poster (PDF)
- Handout: ISPOR 2026 Handout (PDF)
- Value in Health, Volume 29, Issue S6 | Poster EPH177 | Authors: Chintan A. Dalal, PhD; James D. McMichael; Leah Broder, MPH (Socially Determined); Kyle W. McLean, PhD (Veritas)

Description: *Analyzes a national de-identified mortality dataset of approximately one million individuals linking person-level SDOH risk scores with age at death and cause of death. SDOH-based risk ranking identified individuals with approximately 2.7x more premature mortality than expected under uniform prioritization; high-SDOH burden associated with 10-20 years earlier death across leading causes.*

> **Citation:** Dalal CA, McMichael JD, Broder L, McLean KW. Social determinants of health enable early identification of premature mortality risk. Value Health. 2026;29(S6). Presented at: ISPOR 2026; May 2026; Philadelphia, PA. Abstract EPH177.

Northwestern University

High Mortality in Compensated Cirrhosis Amid Limited Transplant Access

Location: ASTS 2026 Winter Symposium | American Journal of Transplantation, Volume 26, Issue 1, Supplement 1, S49 | January 2026

- Conference abstract: American Journal of Transplantation
- Authors: Saad Hussain; Paola Barrios; Hengyi Hu; et al.; Daniela Ladner

Description: *Retrospective CAPriCORN cohort study of 14,346 patients with cirrhosis across 7 health systems in a major US metropolitan area, linking EHR data with SRTR transplant data and Veritas death data. Found low transplant utilization and substantial 1-year mortality even at early cirrhosis stages, with adjusted mortality risk rising sharply by disease stage.*

> **Citation:** Hussain S, Barrios P, Hu H, et al. High mortality in compensated cirrhosis amid limited transplant access. Am J Transplant. 2026;26(1 suppl 1):S49. Presented at: ASTS 2026 Winter Symposium; January 2026; Phoenix, AZ.

Tempus

Validation of a Composite Mortality End Point in a Large Clinicogenomic Real-World Database of Patients With Advanced Cancer

Location: JCO Clinical Cancer Informatics, 2025

- Peer-reviewed article: Peer-reviewed article (JCO Clinical Cancer Informatics)

Description: *This study validates a composite mortality endpoint using real-world clinico-genomic data and explicitly cites Veritas Fact of Death (FOD) mortality data as a core component of the mortality ascertainment methodology.*

> **Citation:** Kapilivsky J, Islam F, Roth EK, Dow J, Moran S, Scherrer E, Hyun SW, Sangli C. Validation of a composite mortality end point in a large clinicogenomic real-world database of patients with advanced cancer. JCO Clin Cancer Inform. 2025;9:e2500291. doi:10.1200/CCI-25-00291

COTA

Validation of a Composite Real-World Mortality Variable Among Patients With Hematologic Malignancies Treated in the United States

Location: JCO Clinical Cancer Informatics, 2025 | Originally presented at ASH Annual Meeting 2023

- Peer-reviewed article: Peer-reviewed article (JCO Clinical Cancer Informatics)

Description: *This publication evaluates a real-world mortality composite in hematologic malignancies. While Veritas Data Research is not explicitly cited by name, the real-world mortality composite referenced in the study was supplied by Veritas Data Research.*

> **Citation:** Dong S, Kansagra AJ, Kaur G, Barcellos A, Belli AJ, Fernandes LL, Hansen E, Ambrose J, Bai C, Zettler CM, Wang CK. Validation of a composite real-world mortality variable among patients with hematologic malignancies treated in the United States. JCO Clin Cancer Inform. 2025;9:e2400233. doi:10.1200/CCI-24-00233

UCB Pharma

A Retrospective Claims Study Evaluating Mortality in Patients With Lennox-Gastaut or Dravet Syndromes in the United States

Location: American Academy of Neurology (AAN) 2025 Annual Meeting | Poster 2784 | San Diego, CA | April 2025 (previously presented at American Epilepsy Society 78th Annual Meeting, December 2024)

- Conference presentation: AAN 2025 Poster
- Authors: Rejena Ameen, PharmD; Elaine C. Wirrell, MD; Joseph Sullivan, MD; Travis Zuroske, MS; Devon Grochowski, MHA; Shalini Gupta, MS (Real Chemistry); Rebecca Zhang Roper, MD, PhD; Amelie Lothe, PhD (UCB); Wesley T. Kerr, MD, PhD

Description: *UCB-sponsored retrospective claims analysis of patients with Lennox-Gastaut syndrome (n=29,626) and Dravet syndrome (n=2,259) in the US, using the Real Chemistry open claims database with mortality status determined from the Veritas mortality dataset. Found standardized mortality ratios 5-9x higher than the general population in both conditions, with cardiovascular/respiratory complications and feeding difficulties most strongly associated with mortality.*

> **Citation**: Ameen R, Wirrell EC, Sullivan J, et al. A retrospective claims study evaluating mortality in patients with Lennox-Gastaut or Dravet syndromes in the United States. Poster 2784. Presented at: American Academy of Neurology 2025 Annual Meeting; April 5-9, 2025; San Diego, CA. Previously presented at: American Epilepsy Society 78th Annual Meeting; December 6-10, 2024; Los Angeles, CA.

IQVIA

Variation in Demographic Characteristics, Socioeconomic Status, Clinical Presentation and Selected Treatments in Mortality Among Patients with a Diagnosis of COVID-19 in the United States

Location: Published article and conference presentation

- Peer-reviewed article: Published article available in PubMed Central (PMC)
- Conference presentation: ISPOR 2023 Poster

Description: *This analysis examines variation in mortality outcomes among COVID-19 patients in the United States and cites Veritas Fact of Death (FOD) data as a mortality data source.*

> **Citation:** Wade RL, Doshi R, Tian D. Variation in demographic characteristics, socioeconomic status, clinical presentation and selected treatments in mortality among patients with a diagnosis of COVID-19 in the United States. Value Health. 2023;26(6 suppl):S319. doi:10.1016/j.jval.2023.03.2056. Presented at: ISPOR 2023; May 2023.